医学
循环肿瘤DNA
内科学
肿瘤科
微小残留病
免疫疗法
神秘的
彭布罗利珠单抗
前瞻性队列研究
佐剂
种系突变
癌症
原发性肿瘤
突变
肿瘤
封锁
胃肠病学
切除术
抗体
循环肿瘤细胞
安慰剂
辅助治疗
临床试验
临床意义
外科
化疗
疾病
临床研究阶段
作者
Y.Y. Janjigian,M.A. Lumish,M.B. Foote,F. Socolow,E. Perissinotto,M. Darmofal,M. Madwed,M. Segal,A. Yaqubie,M. Capanu,J.F. Chou,S.B. Maron,G.Y. Ku,L.B. Saltz,J. Garcia-Aguilar,M.R. Weiser,J.A. Konner,R. Guo,V.E. Strong,E. Jewell
标识
DOI:10.1016/j.annonc.2026.11.005
摘要
BACKGROUND: Detection of circulating tumor DNA (ctDNA) harboring mutations that match those identified in resected tumor tissue signals occult residual disease after curative-intent surgery. Such patients are considered minimal residual disease (MRD)-positive and at high risk for recurrence and death. Few studies have shown that therapeutic intervention can alter recurrence risk in MRD-positive patients. We evaluated whether PD-1 blockade could reduce recurrence in MRD-positive patients with mismatch repair-deficient (dMMR) tumors after curative-intent resection regardless of tumor site of origin. PATIENTS AND METHODS: We initiated a prospective phase II interventional study in patients who had undergone curative-intent resection of early-stage dMMR tumors from any anatomic site. Postoperative MRD status was assessed by first identifying those patients who had detectable ctDNA and then confirming the ctDNA relevance to MRD by matching mutations detected in ctDNA to somatic mutations detected in resected tumor tissue. Confirmed MRD-positive patients received 6 months of PD-1 blockade and were evaluated for ctDNA clearance and 24-month recurrence-free survival (RFS). MRD-negative patients underwent observation. RESULTS: We screened 184 patients with early-stage dMMR solid tumors after curative resection and tumor sequencing with ctDNA testing for MRD assessment. Twenty-three patients (12.5%) were MRD-positive; after excluding one assigned to placebo and three with synchronous radiographic disease, 19 were eligible. Six developed recurrences before pembrolizumab initiation despite being disease-free at enrollment. The remaining 13 MRD-positive patients received 6 months of PD-1 blockade. ctDNA clearance at 6 months was achieved in 11 of 13 patients (85%). Five treated patients (38%) developed recurrence during follow-up. Median follow-up for the MRD-positive patients was 59 months (95% CI: 52-NR). Among 152 MRD-negative patients managed with observation, 14 (9%) developed recurrence during follow-up; 2-year RFS was 92%. CONCLUSIONS: These findings provide evidence that ctDNA-guided adjuvant therapy may offer clinical benefit in dMMR tumors regardless of tissue of origin.
科研通智能强力驱动
Strongly Powered by AbleSci AI